Transforming growth factor beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon.
In a semiquantitative assessment of the expression of transforming growth factor (TGF) beta 1 in liver biopsy specimens from patients with chronic hepatitis C, treatment with interferon alfa-2b (3 million units (MU) three times weekly) decreased the expression of TGF beta 1 in six of seven patients. The reduction in TGF beta 1 correlated significantly with the scores for inflammation (p < 0.05) and necrosis (p < 0.05), but not with the alanine aminotransferase activities (p = 0.36) or the score for fibrosis (p = 0.86).
Bedossa
P
P
Laboratoire d'Anatomie Pathologique, Hôpital Antoine Beclere, Clamart, Paris, France.
Poynard
T
T
Mathurin
P
P
Lemaigre
G
G
Chaput
J C
JC
D000328:Adult; D000368:Aged; D005260:Female; D006526:Hepatitis C / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D006521:Hepatitis, Chronic / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D006801:Humans; D007150:Immunohistochemistry; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000378:metabolism*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta